Bill · H.R. 8857· House(119-HR-8857)
Next GEN Act of 2026
- Introduced
- 5/15/2026
- Last activity
- 5/15/2026 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sponsored by
- Joseph Morelle
- Cosponsors
- - 2 - 2
- Introduced
- In Committee
What this bill would do
This bill, known as the "Next Generation Medicines Act of 2026," proposes to amend title XI of the Social Security Act. The main goal is to adjust the rules for engineered cyclic peptides within the Drug Price Negotiation Program. It specifically changes the time period for these drugs from 7 years to 11 years. The bill provides a specific definition for what qualifies as an "engineered cyclic peptide." These changes would apply to lists published on or after the date the act is enacted.
Yes
Does this make patent and copyright rules fairer?+3
The bill provides extended market exclusivity for a specific class of engineered medicines, which favors pharmaceutical innovation incentives.
The opposite· 3 of 9
Does this lower the price of prescription medicines?-3
The bill delays the price negotiation of engineered cyclic peptides from 7 years to 11 years, potentially keeping prices higher for longer.
Would people over 65 be better off under this?-2
Seniors who rely on Medicare may face higher costs for engineered cyclic peptide drugs for a longer period due to delayed price negotiations.
Would households on low incomes be better off under this?-2
Delayed drug price negotiations can lead to higher out-of-pocket costs for essential medications for low-income individuals.
Who it would affect, and how
Potential Positive Impacts for People
- Extended protection for specific drugs: For drugs classified as an engineered cyclic peptide, the time period is increased from 7 years to 11 years (Section 2(a)(1)). This change adjusts which drugs are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
Potential Negative Impacts for People
- Changes to the Drug Price Negotiation Program: The bill adjusts the timeframes used for qualifying single source drugs (Section 2(a)(1)). This modification impacts how the Drug Price Negotiation Program treats engineered cyclic peptides.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Low Income Households-2Good For Middle Class Households-2Good For People With Disabilities-2Good For Retirees-2Good For Seniors-2Good For Veterans-2
- Economy And Finance
- Improves Consumer Protection-2Reduces Government Spending-2
- Education And Technology
- Improves Intellectual Property Fairness+3
- Healthcare
- Reduces Prescription Drug Costs-3
- 8/27/2026
- 1 Cosponsor added.
- 5/15/2026
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 3 Cosponsors added.
- Introduced in House
Donald DavisDemocrat · North Carolina
Josh GottheimerDemocrat · New Jersey
Thomas KeanRepublican · New Jersey
August PflugerRepublican · Texas